Free Trial

Enveric Biosciences (ENVB) Competitors

Enveric Biosciences logo
$1.31 -0.01 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$1.28 -0.03 (-2.29%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENVB vs. EQ, BCDA, IBIO, SNPX, NERV, BIVI, ALVR, BTAI, AIMD, and ABP

Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Equillium (EQ), BioCardia (BCDA), iBio (IBIO), Synaptogenix (SNPX), Minerva Neurosciences (NERV), BioVie (BIVI), AlloVir (ALVR), BioXcel Therapeutics (BTAI), Ainos (AIMD), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry.

Enveric Biosciences vs. Its Competitors

Enveric Biosciences (NASDAQ:ENVB) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 1.1% of Enveric Biosciences shares are held by company insiders. Comparatively, 31.6% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Equillium has higher revenue and earnings than Enveric Biosciences. Equillium is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$9.57M-$38.38-0.03
Equillium$30.41M0.47-$8.07M-$0.39-1.03

Enveric Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 663.36%. Equillium has a consensus price target of $3.00, suggesting a potential upside of 644.97%. Given Enveric Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Enveric Biosciences is more favorable than Equillium.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Equillium
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Enveric Biosciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.

In the previous week, Enveric Biosciences had 2 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Enveric Biosciences and 1 mentions for Equillium. Equillium's average media sentiment score of 1.89 beat Enveric Biosciences' score of 0.84 indicating that Equillium is being referred to more favorably in the news media.

Company Overall Sentiment
Enveric Biosciences Positive
Equillium Very Positive

Enveric Biosciences has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -250.28% -195.57%
Equillium -19.62%-74.34%-46.75%

Summary

Equillium beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENVB vs. The Competition

MetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.26M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.0321.0428.0720.05
Price / SalesN/A284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book0.568.378.665.87
Net Income-$9.57M-$55.19M$3.25B$258.55M
7 Day Performance-0.76%5.89%4.20%2.23%
1 Month Performance5.65%17.63%10.82%12.76%
1 Year Performance-81.46%5.09%34.70%19.36%

Enveric Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENVB
Enveric Biosciences
2.3344 of 5 stars
$1.31
-0.8%
$10.00
+663.4%
-81.6%$3.26MN/A-0.0320Gap Up
EQ
Equillium
2.9663 of 5 stars
$0.37
+4.8%
$3.00
+718.3%
-58.4%$13.10M$41.10M-0.9440Positive News
Gap Up
BCDA
BioCardia
3.4971 of 5 stars
$2.33
-2.5%
$25.00
+973.0%
-18.7%$12.82M$60K-1.0040Positive News
IBIO
iBio
1.2553 of 5 stars
$0.76
-6.7%
$4.30
+465.8%
-65.8%$12.55M$375K0.00100
SNPX
Synaptogenix
0.0429 of 5 stars
$8.99
+12.7%
N/A+130.6%$12.50MN/A-0.894High Trading Volume
NERV
Minerva Neurosciences
4.4112 of 5 stars
$1.78
+6.0%
$5.00
+180.9%
-32.4%$12.44MN/A2.179Positive News
BIVI
BioVie
0.7648 of 5 stars
$6.62
-7.3%
N/A+85.4%$12.31MN/A-0.0810News Coverage
ALVR
AlloVir
N/A$2.43
-2.8%
N/A-83.9%$12.25MN/A-0.12110High Trading Volume
BTAI
BioXcel Therapeutics
3.964 of 5 stars
$2.02
+2.5%
$42.60
+2,008.9%
-90.8%$12.24M$2.27M-0.1590Gap Up
AIMD
Ainos
1.5558 of 5 stars
$2.88
-3.4%
N/A-24.0%$12.07M$20K-0.4540
ABP
Abpro
N/A$0.20
-4.2%
$4.00
+1,921.2%
N/A$12.03M$183K0.0015Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:ENVB) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners